VERNACI, GRAZIA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 960
EU - Europa 130
AS - Asia 78
AF - Africa 6
SA - Sud America 1
Totale 1.175
Nazione #
US - Stati Uniti d'America 958
IT - Italia 72
CN - Cina 63
FI - Finlandia 23
SE - Svezia 15
EG - Egitto 6
HK - Hong Kong 6
IN - India 6
DE - Germania 5
GB - Regno Unito 5
IE - Irlanda 5
BE - Belgio 2
FR - Francia 2
MX - Messico 2
CH - Svizzera 1
EC - Ecuador 1
IR - Iran 1
JP - Giappone 1
MY - Malesia 1
Totale 1.175
Città #
Chandler 172
Fairfield 143
Ashburn 90
Woodbridge 82
Cambridge 56
Houston 56
Seattle 56
Wilmington 41
Ann Arbor 37
San Diego 22
Helsinki 21
Beijing 17
Medford 16
Princeton 16
Des Moines 12
Roxbury 12
New York 10
Padova 10
Cagliari 7
Cairo 6
Codogno 6
Jinan 6
Boardman 5
Dublin 5
London 5
Milan 4
Nanjing 4
Rome 4
Selvazzano Dentro 4
Venice 4
Changsha 3
Los Angeles 3
Nanchang 3
Pune 3
Bergamo 2
Brussels 2
Cologne 2
Guangzhou 2
Lappeenranta 2
Paris 2
Piove Di Sacco 2
Shenyang 2
Terni 2
Tianjin 2
Tijuana 2
Turin 2
Viareggio 2
Washington 2
Baotou 1
Brookline 1
Colognola 1
Hangzhou 1
Hebei 1
Hefei 1
Kuala Lumpur 1
Kunming 1
Lanzhou 1
Marche 1
Ogden 1
Quito 1
Redwood City 1
Shanghai 1
Sona 1
Taiyuan 1
Taizhou 1
Tehran 1
Tokyo 1
Zhengzhou 1
Zurich 1
Totale 990
Nome #
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 127
Immune characterization of breast cancer metastases: Prognostic implications 120
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 119
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 118
Escalation and de-escalation in HER2 positive early breast cancer 116
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 83
HER2-Positive Early Breast Cancer 74
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 61
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 61
Evolution of HER2-low expression from primary to recurrent breast cancer 53
Efficacia di immunoterapia e chemioterapia come trattamento neoadiuvante nel carcinoma mammario Luminal B-like: risultati dello studio di fase II GIADA. 46
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 45
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 42
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 36
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 35
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 30
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 18
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 13
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 9
Totale 1.206
Categoria #
all - tutte 5.391
article - articoli 4.658
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 288
Totale 10.337


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 0 0 11 11
2019/2020284 8 3 14 95 20 9 24 27 31 28 16 9
2020/2021188 5 9 10 6 23 14 22 15 21 29 25 9
2021/2022227 7 10 10 20 21 22 29 12 15 9 13 59
2022/2023294 39 43 19 54 25 34 8 15 37 1 16 3
2023/2024179 20 24 25 17 18 29 20 15 4 7 0 0
Totale 1.206